Skullcapflavone II alleviates osteoarthritis by inhibiting inflammation and ferroptosis via the SLC7A11/GPX4 signaling pathway
The Journal of Immunology · 04.08.2026 · 215 (8)
DOI: 10.1093/jimmun/vkag230 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 10.08.2026. Verfasst von Jianing Lu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Ward 1, Orthopedics Hospital, The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan, China. Hauptthemen laut MEDLINE: Ferroptosis, Phospholipid Hydroperoxide Glutathione Peroxidase, Amino Acid Transport System y+, Osteoarthritis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
Osteoarthritis (OA), the most prevalent degenerative joint disease, leads to significant disability in the elderly and is characterized by functional and structural deterioration of the knee joint. This study aimed to investigate the therapeutic potential of skullcapflavone II (SkII), a flavonoid known for its anti-inflammatory properties, in the context of OA. Our results demonstrated that SkII markedly suppressed IL-1β–induced extracellular matrix degradation and apoptosis in chondrocytes. Furthermore, SkII reduced reactive oxygen species and malondialdehyde levels while enhancing superoxide dismutase activity and the glutathione/glutathione disulfide ratio. SkII also upregulated the expression of SLC7A11 and glutathione peroxidase 4 (GPX4). Mechanistic investigations revealed that SkII, similar to the ferroptosis inhibitor ferrostatin-1, effectively counteracted erastin-induced apoptosis and extracellular matrix degradation. Both SkII and ferrostatin-1 promoted SLC7A11 and GPX4 expression at transcriptional and protein levels and diminished ferrous ion (Fe2+) accumulation in chondrocytes. In vivo experiments confirmed that SkII treatment attenuated ferroptosis in OA rats by activating the SLC7A11/GPX4 pathway. In conclusion, our findings indicate that SkII alleviates OA progression by inhibiting ferroptosis through the SLC7A11/GPX4 signaling axis. These results underscore the potential of SkII as a promising therapeutic candidate for the treatment and prevention of OA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ward 1, Orthopedics Hospital, The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan, China.
- Ward 2, Orthopedics Hospital, The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan, China.
Zitieren
APA
Lu, J., Lian, Y., Ru, Q., Guo, X., Han, B., & Liu, Y. (2026). Skullcapflavone II alleviates osteoarthritis by inhibiting inflammation and ferroptosis via the SLC7A11/GPX4 signaling pathway. The Journal of Immunology, 215(8). https://doi.org/10.1093/jimmun/vkag230
Vancouver
Lu J, Lian Y, Ru Q, Guo X, Han B, Liu Y. Skullcapflavone II alleviates osteoarthritis by inhibiting inflammation and ferroptosis via the SLC7A11/GPX4 signaling pathway. The Journal of Immunology. 2026;215(8). doi:10.1093/jimmun/vkag230
BibTeX
@article{Lu2026,
author = {Lu, Jianing and Lian, Yijun and Ru, Qingchao and Guo, Xin and Han, Bowen and Liu, Yang},
title = {Skullcapflavone II alleviates osteoarthritis by inhibiting inflammation and ferroptosis via the SLC7A11/GPX4 signaling pathway},
journal = {The Journal of Immunology},
year = {2026},
volume = {215},
number = {8},
doi = {10.1093/jimmun/vkag230}
}
EUVIMED